产品名称

Pexidartinib - PLX 3397

产品货号

Axon 2501 CAS [1029044-16-3] MF C20H15ClF3N5MW 417.81 Purity: 99% Soluble in DMSO Description Multi-targeted receptor tyrosine kinase inhibitor of CSF1R, c-Kit, and FLT3 (IC50 values 13 nM, 27 nM, and 11 nM, respectively) Administration of PLX3397 reduced CIBP, induced substantial intratumoral fibrosis, and was also highly efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor-induced bone remodeling. PLX3397 is superior to imatinib in the treatment of malignant peripheral nerve sheath tumor (MPNST), and the combination of PLX3397 with a TORC1 inhibitor could provide a new therapeutic approach for the treatment of this disease. KEYWORDS: Pexidartinib | supplier | RTK inhibitor | PLX 3397 | PLX3397 | CAS [1029044-16-3] | FLT3LG | FLT3 | c-KIT | CSF1R | cytokine | tyrosine kinase | CIBP | MPNST | TORC1 | cluster of differentiation | hematopoietic | stem cell factor | SCF

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Pexidartinib - PLX 3397

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2501

CAS [1029044-16-3]

MF C20H15ClF3N5
MW 417.81

Purity: 99%
Soluble in DMSO

Pexidartinib

Description

Multi-targeted receptor tyrosine kinase inhibitor of CSF1R, c-Kit, and FLT3 (IC50 values 13 nM, 27 nM, and 11 nM, respectively) Administration of PLX3397 reduced CIBP, induced substantial intratumoral fibrosis, and was also highly efficacious in reducing tumor cell growth, formation of new tumor colonies in bone, and pathological tumor-induced bone remodeling. PLX3397 is superior to imatinib in the treatment of malignant peripheral nerve sheath tumor (MPNST), and the combination of PLX3397 with a TORC1 inhibitor could provide a new therapeutic approach for the treatment of this disease.